Masanori Inoue
A5050183765- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Cancer, Lipids, and Metabolism
- Glaucoma and retinal disorders
- Cancer Mechanisms and Therapy
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Economic and Financial Impacts of Cancer
- Retinal Development and Disorders
- Biochemical effects in animals
- Retinal Diseases and Treatments
- Photoreceptor and optogenetics research
- Hepatitis C virus research
- Vascular Anomalies and Treatments
- Cancer Immunotherapy and Biomarkers
- Neurological Disorders and Treatments
- Retinal Imaging and Analysis
- Liver Disease and Transplantation
- Pharmacological Effects of Natural Compounds
- Neuroendocrine Tumor Research Advances
- Hernia repair and management
- Radiomics and Machine Learning in Medical Imaging
- Vascular Malformations and Hemangiomas
Chiba University
2012-2024
Keio University
2012-2024
Fujita Health University
2024
Numazu City Hospital
2021-2022
Asahi General Hospital
2019-2021
Chiba University Hospital
2021
Okayama University Hospital
2019
Sapporo Kosei General Hospital
2018
Nihon University
2004-2014
Keio University Hospital
2012
The present study aimed to assess the efficacy and safety of lenvatinib verify possibility for expanded indication from REFLECT trial in patients with advanced hepatocellular carcinoma (HCC) real-world practice, primarily focusing on population that was excluded trial.We retrospectively collected data HCC who were administered 7 institutions Japan.Of 152 patients, 95 57 received first-line second- or later-line systemic therapies, respectively. median progression-free survival Child-Pugh...
The prognosis of patients with advanced hepatocellular carcinoma (HCC) is expected to improve as multiple molecular target agents (MTAs) are now available. However, the impact availability sequential MTAs has not been fully verified yet.We retrospectively collected data on whole clinical course 877 who received any first-line systemic therapy for HCC between June 2009 and March 2019. study population was divided into 3 groups according date MTA administration (period 1: 2009-2012, n = 267;...
There is no standard posttreatment for patients with advanced hepatocellular carcinoma (HCC) in whom lenvatinib therapy has failed. This study aimed to investigate rates of migration after and explore candidates second-line agents the failed therapy.We retrospectively collected data on HCC who received as first-line agent 7 institutions.Overall survival progression-free (PFS) 178 were 13.3 months (95% confidence interval [CI], 11.5-15.2) 6.7 CI, 5.6-7.8), respectively. Sixty-nine 151 (45.7%)...
Abstract Purpose: This study aimed to investigate the safety and efficacy of lenvatinib in real-world settings, including patients excluded from REFLECT trial, a phase III trial that compared with sorafenib. Patients Methods: multicenter, nonrandomized, open-label prospective was conducted at 10 medical facilities Japan (jRCTs031190017). Eligible had advanced hepatocellular carcinoma (HCC) were suitable for therapy. The included high tumor burden (with >50% intrahepatic volume, main...
Histone H3 lysine 9 dimethylation (H3K9me2) is mainly regulated by the histone methyltransferase G9a and associated with repression of transcription. However, both role significance H3K9me2 in hepatocellular carcinoma (HCC) cells remain unclear. In this study, we conducted loss-of-function assay using short-hairpin RNA pharmacological interference. Knockdown reduced levels impaired HCC cell growth sphere formation. transforming factor β1-induced epithelial mesenchymal transition (EMT) was...
Several abnormalities in visual pathway functions diabetic humans and animals have been reported. We demonstrated retrograde axonal transport impairment retinal ganglion cells of streptozotocin-diabetic rats.Diabetes was induced male Wistar albino rats by intraperitoneal injection streptozotocin. Three months after the induction diabetes, fluoro-gold injected into dorsal lateral geniculate nucleus. Percentages fluoro-gold-labeled large-, medium- small-sized per total population were...
Abstract Background During systemic therapy, the management of portal hypertension (PH)-related complications is vital. This study aimed to clarify factors associated with incidence and exacerbation PH-related complications, including usefulness contrast-enhanced computed tomography (CECT) in during therapy. Methods A total 669 patients who received therapy as first-line treatment (443 for sorafenib, 131 lenvatinib, 90 atezolizumab/bevacizumab [ATZ/BEV]) were enrolled this retrospective...
Abstract Background Although the efficacy of atezolizumab has been demonstrated in randomized controlled trials, its long‐term and association with adverse events real‐world practice are unknown. This study was designed to shed light on these issues. Methods In this multicenter retrospective study, data were collected from patients advanced hepatocellular carcinoma treated plus bevacizumab seven institutions Japan. The authors focused related vascular endothelial growth factor (VEGF)...
Abstract The objective was to prepare guidelines perform the current optimum treatment by organizing effective and efficient treatments of hemangiomas vascular malformations, confirming safety, systematizing treatment, employing evidence-based medicine (EBM) techniques aimed at improvement outcomes. Clinical questions (CQs) were decided based on important clinical issues. For document retrieval, key words for literature searches set each CQ published from 1980 end September 2014 searched in...
Abstract The objective was to prepare guidelines perform the current optimum treatment by organizing effective and efficient treatments of hemangiomas vascular malformations, confirming safety, systematizing treatment, employing evidence‐based medicine (EBM) techniques aimed at improvement outcomes. Clinical questions (CQs) were decided based on important clinical issues. For document retrieval, key words for literature searches set each CQ published from 1980 end September 2014 searched in...
Abstract The objective was to prepare guidelines perform the current optimum treatment by organizing effective and efficient treatments of hemangiomas vascular malformations, confirming safety systematizing treatment, employing evidence‐based medicine techniques aimed at improvement outcomes. Clinical questions (CQ) were decided based on important clinical issues. For document retrieval, key words for published work searches set each CQ, from 1980 end September 2014 searched in PubMed,...
An 81-year-old man was admitted to our hospital because of right quadrant abdominal pain. On admission, his liver function Child-Pugh grade C (10 points). Computed tomography (CT) revealed a diaphragmatic herniation bowel loops into the thoracic cavity, accompanied by pleural effusion. Although hernia successfully repaired emergency surgery, he died failure 23 days after surgery. A retrospective reading CT images presence injury radiofrequency ablation (RFA) which had been conducted 33...
Abstract Background Hyperprogressive disease (HPD) is a phenomenon with greatly accelerated tumor growth and clinical deterioration rates compared to pre-therapy, in patients treated immune checkpoint inhibitors (ICI). The aim of this study clarify the reality HPD advanced hepatocellular carcinoma (HCC) who were atezolizumab plus bevacizumab (Atez/Bev) using dynamics. Methods Medical records consecutive HCC Atez/Bev retrospectively reviewed. was defined as more than two- or fourfold increase...
Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) performed before curative therapy for hepatocellular carcinoma (HCC) can distinguish between intrahepatic distant recurrence and hypervascularization. This study aimed to retrospectively evaluate the presence of non-hypervascular hypointense nodules on hepatobiliary phase images from Gd-EOB-DTPA-enhanced MRI as a risk factor early stage HCC following radiofrequency ablation...
<b><i>Background:</i></b> Intermediate-stage hepatocellular carcinoma (HCC) has a high frequency of recurrence and progression to advanced stage after transarterial chemoembolization (TACE), particularly in patients with tumor burden. Promising new results from immune checkpoint inhibitors (ICIs) ICI-based therapies are expected replace TACE, especially HCC <b><i>Aims:</i></b> The present study aimed evaluate the effectiveness TACE view design...